32 results about "Anti-emetic" patented technology

The invention relates to an Oral Delayed Immediate Release formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids. The invention further relates to formulations containing an Immediate Release formulation combined with one or more Oral Delayed Immediate Release formulations with different lag-times and to a method of preparing an Oral Delayed Immediate Release formulation.The Oral Delayed Immediate Release formulation may be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere compounds, anti-hypertensives, sedatives, anti-depressants, anti-anxiety compounds, cortico-steroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics, anti-aritmics, anti-rheumatics, anti-arthritic compounds and anti-angina compounds.The Oral Delayed Immediate Release formulation may also be used for the application of biological active compounds such as proteins, peptides, enzymes, vaccines and oligonucleotides.

The topical medicament gel formulation of the present invention includes an anesthetic, an anti-microbial, an oxidant, a nutrient, a diuretic, an opioid, an anti-emetic, an anti-seizure drug, and a non-steroidal anti-inflammatory drug (NSAID), USP in a molecular, as opposed to a salt form, as the active ingredient. Additional constituents illustratively include a skin penetration enhancer and a gelling agent. This invention deals with problems commonly associated with topical application of local medicaments such as: slow onset of action; need for occlusion; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the medicament and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK₁) receptor. The compounds have the general formula (I):

The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, (3R,4R)-Δ⁸-THC-11-oic acids, for treating or preventing nausea and relieving symptoms thereof.

The invention relates to a dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method, which can industrially prepare both liposome medicine-carrying injections and liposome medicine-carrying oral preparations by utilizing uniform prescriptions, technologies and devices. The invention provides a mole-ratio prescription of various components and materials for preparing liposome medicine-carrying preparations, and provides a technology for preparing nanoliposome lyophilization injections and liposome oral preparations. The invention also provides 20 embodiments for preparing liposome medicine-carrying preparations: an embodiment for preparing anti-gastric-ulcer liposome medicine-carrying preparations, an embodiment for preparing antibiosis and anti-fungus liposome medicine-carrying preparations, an embodiment for preparing anti-tumor liposome medicine-carrying preparations, an embodiment for preparing anti-viral liposome medicine-carrying preparations, an embodiment for preparing anti-emetic liposome medicine-carrying preparations, an embodiment for preparing nutrition-supplement liposome medicine-carrying preparations and an embodiment for preparing anti-diabetics and cardio- and cerebro-vascular drug liposome medicine-carrying preparations.

Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.

According to the invention, a liposome combination drug injection and an oral liposome combination drug preparation can be produced in a large industrialization manner through a molecular dispersion method with a unified formula, a unified process and unified equipment. The invention provides a formula of raw components for preparing liposome combination drugs in a molar ratio, provides freeze-drying injection and oral preparation processes for the prepared liposome combination drugs, and also provides twenty embodiments for preparing the liposome combination drugs, such as an anti-gastric-ulcer liposome combination drug, antibacterial and antifungal liposome combination drugs, an anti-tumor liposome combination drug, an anti-virus liposome combination drug, an anti-emetic liposome combination drug, a nutritional supplement liposome combination drug and hypoglycemic agent and cardiovascular medicine liposome combination drugs.

The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of functional gastrointestinal disorders, such as irritable bowel disease and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included is the combination of PYY or functional equivalents thereof with a secondary active ingredient such as an anti-emetic drug.

The orally disintegrated granisetron tablet as antiemetic is prepared with granisetron hydrochloride as main medicine component, hydroxyethyl cellulose and other medicinal supplementary material. After being taken, the antiemetic may be disintegrated fast in orally and swallowed into digestive tract without need water to produce excellent effect of preventing and treating nausean and vomiting caused by chemotherapy, radiotherapy and surgical operation. The present invention has low production cost.

The present invention provides a transdermal delivery system for hydrophilic anti-emetic agents and methods of using thereof. The system includes an anti-emetic hydrophilic adhesive composition of a hydrophilic polymer and hydrophilic anti-emetic agent, a patch containing at least one hydrophilic layer of the composition, and an apparatus that generates hydrophilic micro-channels in skin of a subject using the patch or composition. The system preferably avoids the use of penetration enhancers and is particularly useful for transdermal delivery of hydrophilic anti-emetic agents.

A compound for consumption by cancer patients, or others currently suffering from side effects such as those commonly associated with chemotherapy, that supplies herbal tonics with certain properties believed to ameliorate many of the side effects discussed above, and which has taste masking properties that improve the patient's tolerance of the supplement and likelihood to consistently consume the supplement. The compound is a mixture generally containing three core components: whey protein, which has a number of significant health benefits for cancer patients; hepatoprotectant and/or nephroprotectant agents(s), which reduce damage to the kidneys and liver; and anti-emetic agent(s), which reduce nausea and vomiting.

The invention discloses a plaster type oral esophagus medicine-applying treatment device and a plaster type oral esophagus medicine-applying treatment method. The device comprises a center hole plug joint body and an anti-emetic sleeve, wherein the center hole plug joint body is formed by connecting a first joint and a second joint in parallel; one end of the first joint is connected with an adsorbent connecting pipe, and the other end of the first joint is connected with an adsorbent conveying ventilation pipe; and one end of the second joint is connected with a therapeutic medicine connecting pipe, and the other end of the second joint is connected with a therapeutic medicine conveying ventilation pipe. When the device is used, an adsorbent and a therapeutic medicine are sequentially sprayed to a wounded part. The device is simple in structure, a direct effect is achieved, the medicine can be effectively applied to the wounded part in a plaster applying mode, a medicine effect is kept for a long time, and the medicine is not easy to fall off.

The invention discloses an anti-emetic auxiliary feeding device. The anti-emetic auxiliary feeding device comprises a feeding channel pipe and an anti-emetic feeding pipe guide sleeve, wherein the anti-emetic feeding pipe guide sleeve is sleeved on the feeding channel pipe; the feeding channel pipe is formed by sequentially connecting an outer funnel area, an inner funnel area and a flexible pipe; and the anti-emetic feeding pipe guide sleeve is formed by connecting an extension pipe and a guide sleeve. The anti-emetic auxiliary feeding device is simple in structure and convenient to use; and the feeding safety of a patient is ensured.

Composition and formulations comprises a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s)such as analgesics, muscle relaxants, mood disorder agents, anti-inflammatories, anti-migraine agents, anti-emetics, diuretics, high protein composites, and the like. The products are suitable as nociceptics and for the treatment of wasting disorders, bulimia, anorexia nervosa, anxiety, irritability and other symptoms associated with Pre Menstrual Syndrome, as well as for administration either in conjunction with steroids or to compensate adenosine depletion and/or bizarre behavior or aggression common in steroid users.